Business
SeaStar Medical Appoints David A. Green as Chief Financial Officer
DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to
About this update from Seastar Medical Holding Corporation
[{"type":"text","content":"DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the appointment of healthcare industry veteran David A. Green as Chief Financial Officer, effective January 10, 2024. Caryl Baron, who has served as Interim CFO since October 2022, will continue with SeaStar Medical as Vice President of Finance. “We welcome David to our executive team at this critical time as we prepare for our first commercial launch for the Selected Cytopheretic Device Pediatric (SCD-PED) later this quarter,” said Eric Schlorff, CEO of SeaStar Medical. “David’s extensive financial experience at public medical device and therapeutics companies will be highly valuable as we work to bring our groundbreaking solutions to those with devastating hyperinflammation. Importantly, David shares our commitment to improving patient outcomes and saving lives. “On behalf of the entire SeaStar Medical team, I extend our thanks to Caryl for stepping into the CFO position on an interim basis during our transition to public company status. We look forward to her continued service to our Company.” “SeaStar Medical’s cell-directed extracorporeal therapy holds potential in multiple high-value indications to stop the threat of a dysregulated inflammatory response that can cause organ damage and even death, while also reducing healthcare system costs,” said Mr. Green. “I’m excited to join this talented, focused and highly motivated team.” Mr. Green has more than 25 years of financial experience primarily in the healthcare sector. He previously served as Interim CFO of Prolacta Bioscience, a private company providing specialized nutrition products to critically ill premature infants, where he led efforts to pursue an initial public offering. Prior to Prolacta, he was Executive Vice President and CFO of Aytu BioPharma, a publicly traded specialty pharmaceutical and medical device company marketing prescription and over-the-counter products. In this position, he completed multiple financing transactions and was instrumental in the company’s M&A activities. Earlier, he was Chief Accounting Officer at Intarcia Therapeutics, a commercial-stage biopharmaceutical company; CFO of Catheter Connections, a commercial-stage ...